Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia

NCT05369377 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia

Interventions

DRUG: Zanubrutinib
DRUG: Eltrombopag

Sponsor

Peking University People's Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]